PropertyValue
nif:beginIndex
  • 0 (xsd:integer)
nif:broaderContext
nif:endIndex
  • 271 (xsd:integer)
nif:isString
  • In a retrospective analysis of 14 VHL patients, Roma et al reported partial response to sunitinib in 64% of different VHL tumors (progressive renal cell carcinomas; and pancreatic, adrenal and ovarian lesions), yielding a progression-free survival of 71.4% after 2 years.
rdf:type